Navigation Links
Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Date:4/30/2008

-time awakenings reported by the patient at 6 and 12 weeks, versus placebo and improves the quality of sleep.

The results of the GEMS study also confirm the product's good tolerance profile versus placebo, with no residual effect on waking and with no rebound phenomenon nor withdrawal symptoms after treatment cessation, as already demonstrated in EPLILONG and EPOCH.

Sanofi-aventis also announces the results of the first phase III study (NOCTURNE) conducted with volinanserin (second 5-HT2A antagonist developed for the treatment of insomnia characterized by sleep maintenance difficulties / night-time awakenings) which showed that volinanserin significantly reduces WASO and the number of night-time awakenings (measured by polysomnography) at 3 and 6 weeks of treatment, versus placebo. The results also demonstrate the good safety profile of volinanserin versus placebo. Two other Phase III studies versus placebo are currently on-going.

Saredutant : the INDIGO study (EFC5574 in elderly) results on saredutant are also released today. The study did not reach significance versus placebo (same for the comparator).

It is notable that the effect size obtained in INDIGO is in the same range than that of the non-elderly population. The pooled analysis of all saredutant studies demonstrates a positive short term benefit on patients suffering from MDD as measured by the HAM-D score.

Results of the maintenance trial will be available in the second half of 2008. Trials associating saredutant with an SSRI are on-going.

As expected by its new MoA, saredutant lacks side effects frequently observed with current antidepressants. This was confirmed in the INDIGO elderly study.

Multaq(R) : the results of the ATHENA study, evaluating the potential benefits of Multaq(R) on morbidity and mortality, are due to be presented to the American Heart Rate Society in San Francisco on May 15, 2008 at 10.30 hours local time (19.30 hours CET).

<
'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Free Health Clinic Event Is Not Just for the Sick 2
...State University researchers have now developed a ...marrow derived stem cells to be grown in sufficien... faster growth of// tissues. This overcomes the cu...ic conditions encountered by adult stem cells with...
...akthrough, scientists present the first proof that...use of the common cold.// So, if your mother ...g a cold, it seems she may have had a point. ... this week’s The Oxford Journal of Family Practice...
...rnment in its determination to gear up to meet the... committee to keep a close watch on bird flu cases...imal Husbandry Secretary P M A Hakeem said "Though...poultry industry". The Secretary said the Central ...
...sults showed that people who lived longer had a hi...position. The research study was carried out by Dr...ol of Public Health who reported their finding in ... with a score more than 130 are considered gifted ...
...cer and other cancers are mainly caused by cigaret...eases the risk of cancer occurrence. In order to r...merican Tobacco company is in the process of testi...ttes to find its efficacy and carcinogen content e...
...akthrough, which could eventually lead to a practi...irus, scientists from the US National Cancer Insti...the human body to produce chemicals that block HIV...a. The researchers have successfully modifie...
Other Medicine News:Health News:Perfusion bioreactor could enhance stem cell research and application in the future 2Health News:Scientist affirm mother’s advice 2Health News:Avian Influenza: Government to set up expert committee 2Health News:Genetically modified bacteria to combat HIV 2
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Medigap Plans in Illinois to Benefit From Medicare Advantage Reimbursement Cuts 52935 1Medigap Plans in Illinois to Benefit From Medicare Advantage Reimbursement Cuts 52935 2Sunshine Heart Provides C Pulse U S Clinical Update 52931 1Sunshine Heart Provides C Pulse U S Clinical Update 52931 2Sunshine Heart Provides C Pulse U S Clinical Update 52931 3Sunshine Heart Provides C Pulse U S Clinical Update 52931 4Diabetes Screening Comes Home with A1c Testing 52927 1Diabetes Screening Comes Home with A1c Testing 52927 2
...N, Pa., March 14 Isolagen(TM), Inc.,(Amex: ILE )...pproximately,120 patients in its Phase II/III Stud...for the treatment of moderate to severe acne scars...linical sites across the U.S., have,now commenced....at promise for the,treatment of acne scars and are...
... Suggest Majority of Pompe Patients May Be Amenabl...apy, CRANBURY, N.J., March 13 Amicus Therapeutic...lecule, orally administered,pharmacological chaper...nnounced today that the Company will present posit...ee Phase 1 studies of AT2220 (1-deoxynojirimycin,H...
Other Medicine Technology:Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 2Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 4
AHFS Patient Drug Information
The 5 Minute Herb & Dietary Supplement Consult
Quality Module QS I
...mbination of the Aliquoting System RSD 800A with a... turns out in an efficient System and a complete s...all important front-end and back-end features: cen...ation, sample quality control, decapping, barcode ...
Medicine Products: